The DOI matches its Crossref record.
Current Therapy for Crigler–Najjar Syndrome Type 1: Report of A World Registry
Abstract
This study represents a multicenter survey on the management of patients with Crigler–Najjar syndrome (CNS) type 1. The aim of the survey was to find guiding principles for physicians in the care of these patients. Fifty–seven patients were included. At the time of inclusion, 21 patients had received a liver transplant (37%). The average age at transplantation was 9.1 ± 6.9 years (range, 1-23 years); the age of the patients who had not been transplanted at the time of inclusion was 6.9 ± 6.0 years (range, 0-23 years). Brain damage had developed in 15 patients (26%). Five patients died, and 10 are alive with some degree of mental or physical handicap. In 2 patients, ages 22 and 23 years, early signs of bilirubin encephalopathy could be reversed, in 1 by prompt medical intervention followed by liver transplantation and in the other by prompt liver transplantation. Seven patients underwent transplantation with some degree of brain damage at the time of the surgery; 1 of these died after retransplantation, 2 improved neurologically, and 4 remained neurologically impaired. The age of 8 patients with and 13 without brain damage at or before transplantation was 14.3 ± 5.9 and 5.9 ± 5.4 years ( P < .01), respectively. Therapy of CNS type 1 consists of phototherapy (12 h/d), followed by liver transplantation. Phototherapy, although initially very effective, is socially inconvenient and becomes less efficient in the older age group, thus also decreasing compliance. Currently, liver transplantation is the only effective therapy. This survey shows that, in a significant number of patients, liver transplantation is performed after some form of brain damage has already occurred. From this, one must conclude that liver transplantation should be performed at a young age, particularly in situations in which reliable administration of phototherapy cannot be guaranteed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Treatment of the Crigler–Najjar Syndrome Type I with Hepatocyte Transplantation
Fox, I. J., Chowdhury, J. R., Kaufman, S. S., Goertzen, T. C., Chowdhury, N. R., Warkentin, P. I., Dorko, K., Sauter, B. V., & Strom, S. C. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805143382004 · Cited by 1,023
Hepatic steatosis: Innocent bystander or guilty party?
Day, C. P., & James, O. F. W. (1998) · Hepatology · doi:10.1002/hep.510270601 · Cited by 388
Kadakol, A., Ghosh, S. S., Sappal, B. S., Sharma, G., Chowdhury, J. R., & Chowdhury, N. R. (2000) · Human Mutation · doi:10.1002/1098-1004(200010)16:4<297::aid-humu2>3.0.co;2-z · Cited by 387
Bilirubin in clinical practice: a review
Fevery, J. (2008) · Liver International · doi:10.1111/j.1478-3231.2008.01716.x · Cited by 374
Self-citationBilirubin toxicity in the developing nervous system
Shapiro, S. M. (2003) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2003.09.011 · Cited by 350
Inherited disorders of bilirubin metabolism
Bosma, P. J. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00359-8 · Cited by 279
Squires, R. H., Ng, V., Romero, R., Ekong, U., Hardikar, W., Emre, S., & Mazariegos, G. V. (2014) · Hepatology · doi:10.1002/hep.27191 · Cited by 254
Application of whole-organ tissue engineering in hepatology
Uygun, B. E., Yarmush, M. L., & Uygun, K. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.140 · Cited by 76
Apgar, J. F., Tang, J., Singh, P., Balasubramanian, N., Burke, J., Hodges, M. R., Lasaro, M. A., Lin, L., Miliard, B. L., Moore, K., et al. (2018) · CPT: Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12301 · Cited by 47
Metadata
- Authors
- van der Veere, C. N., Sinaasappel, M., McDonagh, A. F., Rosenthal, P., Labrune, P., Odiévre, M., Fevery, J., Otte, J., McClean, P., Bürk, G., Masakowski, V, Sperl, W., Mowat, A. P., Vergani, G. M., Heller, K., Wilson, J. P., Shepherd, R., & Jansen, P. L.
- Venue
- Hepatology
- Published
- 1996-08
- Volume
- 24
- Issue
- 2
- Pages
- 311-315
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2014031811
- Cited by
- 179
- References
- 0
- FWCI
- 4.97
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.